The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million ...

On May 7, 2026, Wells Fargo raised the firm’s price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while ...

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, H.C. Wainwright increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and kept ...

Shares of MannKind Corporation (MNKD) added ~16% in the premarket on Wednesday after the company announced plans for a new jointly developed therapy as part of an expanded license and collaboration ...

MannKind's shares soared after the company revealed it has been developing a dry powder inhalation formulation of ralinepag over the past six months for United Therapeutics. Shares of MannKind climbed ...

Q1 2026 Management view "In the first quarter, we continued to execute our strategy to evolve MannKind to a diversified company positioned to deliver sustained long-term growth," said CEO Michael ...

Biopharmaceutical MannKind, which has its headquarters in Westlake Village, is positioning itself as a med-tech platform. (Courtesy photo) MannKind shares skyrocketed as much as 26% on May 6 after the ...

Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming ...

View MannKind Corporation MNKD stock quote prices, financial information, real-time forecasts, and company news from CNN.

MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest ...

CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr.

There's nothing like an estimate-topping quarter to put some pep in a company. A big jump in royalty revenue was particularly notable. The reason for the stock's jump wasn't hard to tease out.